



Standard of Care in Neovascular AMD

- ANCHOR MARINA
- CATT
- VIEW 1,2



Intravitreal injections protocols

• Fixed dosing (Monthly, bimonthly, quarterly)

"One size fits all" to "individualized" ttt

### Anti-VEGF and Wet AMD

Intravitreal injections protocols

- Fixed dosing
- PRN (As Needed)
- Treat & Extend (T&E)

The definition of disease **ACTIVITY** 

Loss of ≥5 letters in VA

Evidence of new Hge.

IRF and SRF in OCT

CRT increased by >100  $\mu$ m

### Anti-VEGF and Wet AMD


The role of OCT

Base line <u>DIAGNOSIS</u>

Monitoring <u>RESPONSE</u> HOW many injections we are loading? THREE.....OR MORE?


WHEN to say RESISTANT n-AMD ?


WHEN to say RECURRENT n-AMD ?



The role of OCT Monitoring RESPONSE


#### Intra retinal fluids "CYSTS"






The role of OCTMonitoring RESPONSE

Subretinal fluids






### The role of OCT

Do we need to totally "DRY" the macula? Subretinal fluids



The role of OCT


Do we need to totally "DRY" the macula?





### Anti-VEGF and Wet AMD


### The role of OCT

Do we need to totally "DRY" the macula? Chronic Cysts











*The role of OCT* Differentiating n-AMD from PCV


OCT alone without ICG?





The role of OCT


Combination with "OCTA" assessing activity in "long term" not "short term"














### Take home message

B-scan OCT , not only have diagnostic role in n-AMD, but also an important biomarker for disease activity and visual prognosis that can fine tune our ttt algorithms especially if combined with the new technology of OCTA.

#### REFERENCES

Kovach, Jaclyn L. et al. "Anti-VEGF Treatment Strategies for Wet AMD." Journal of Ophthalmology 2012.

Arnold, Jennifer J. et al. "The Role of Sub-Retinal Fluid in Determining Treatment Outcomes in Patients with Neovascular Age-Related Macular Degeneration - a Phase IV Randomised Clinical Trial with Ranibizumab: The FLUID Study." BMC Ophthalmology 2016.

Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Design, Development and Therapy. 2016;10:1857-1867.

*Silva R, Berta A, Larsen M, Macfadden W, Feller C, Monés J;* Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration\_Results with Ranibizumab from the TREND Study .*Ophthalmology.* 2018 Jan;125(1):57-65

Coscas GJ, Lupidi M, Coscas F, Cagini C, Souied EH. optical coherence tomographyangiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge. Retina 2015 Nov;35(11):2219-28

